Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:NXTC

NextCure Q3 2026 Earnings Date & Estimates

NextCure logo
$7.18 +0.40 (+5.90%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.08 -0.10 (-1.41%)
As of 10/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NextCure is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from NextCure in Q3 2026

NextCure is expected to post earnings of -$0.90 per share. In the same quarter a year earlier NextCure reported -$3.22 per share. NextCure last reported on August 6, 2026, posting -$2.80 per share and missing the -$1.95 consensus estimate. NextCure has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.90
Prior-Year EPS
-$3.22

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.80 (Missed by -$0.85)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

NextCure Q3 2026 Earnings FAQ

NextCure (NASDAQ:NXTC) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

NextCure's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect NextCure to post earnings of -$0.90 per share for Q3 2026.

NextCure Earnings Headlines

NextCure Faces Court Review of Reverse Stock Split
September 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NXTC/pressreleases/4818172/nextcure-faces-court-review-of-reverse-stock-split/
NextCure Ends Beltsville Lease to Cut Operating Costs
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nextcure-ends-beltsville-lease-to-cut-operating-costs?utm_source=marketbeat.com&utm_medium=referral
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
October 11 at 1:00 AM  |  Porter & Company (Ad)
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
August 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/avere-therapeutics-announces-500-million-private-placement-to-support-development-of-once-weekly-oral-il-23-therapy-avr-001-302846694.html
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nextcure-provides-business-update-and-reports-second-quarter-2026-financial-results-1036422678
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—VEEE, NXTC, TCBK, and FHB
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332390/0/en/the-m-a-class-action-firm-encourages-hareholders-to-contact-monteverde-concerning-the-merger-veee-nxtc-tcbk-and-fhb.html
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company’s research is centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack tumor cells, with the goal of addressing limitations associated with existing cancer immunotherapies.

NextCure’s pipeline has included investigational antibody-based therapies and other immune-modulating programs targeting mechanisms that can suppress immune responses in the tumor microenvironment. Its lead programs have been evaluated in clinical studies involving patients with advanced solid tumors, including as standalone treatments and in combination with other anticancer therapies.

Founded in 2015 and headquartered in the United States, NextCure has advanced its programs through early-stage clinical development and has conducted research and clinical activities in collaboration with healthcare and pharmaceutical organizations. As a development-stage biotechnology company, its products remain investigational and are subject to clinical, regulatory, and commercial uncertainties.

View NextCure Profile
Earnings Tools